Recombination and functional studies of a dual-action peptide for diabetes.

about

Recombination and functional studies of a dual-action peptide for diabetes.

Item

http://www.wikidata.org/entity/Q44227850

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Recombination and functional studies of a dual-action peptide for diabetes.

@en

Recombination and functional studies of a dual-action peptide for diabetes.

@nl

type

Item

label

Recombination and functional studies of a dual-action peptide for diabetes.

@en

Recombination and functional studies of a dual-action peptide for diabetes.

@nl

prefLabel

Recombination and functional studies of a dual-action peptide for diabetes.

@en

Recombination and functional studies of a dual-action peptide for diabetes.

@nl

P1476

Recombination and functional studies of a dual-action peptide for diabetes.

@en

P2093

Jie Zheng

http://www.w3.org/2001/XMLSchema#string

Ming Zhong

http://www.w3.org/2001/XMLSchema#string

Qiuping Yan

http://www.w3.org/2001/XMLSchema#string

Suqing Zhao

http://www.w3.org/2001/XMLSchema#string

Yu Liu

http://www.w3.org/2001/XMLSchema#string

Yuanchang Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

Advanced glycation end products and diabetic cardiovascular disease.

Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice.

Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis.

Glucagon-like peptide-1 7-36: a physiological incretin in man.

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay.

Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy.

Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population.

Therapeutic effect of green tea extract on advanced glycation and cross-linking of collagen in the aorta of streptozotocin diabetic rats.

P304

443-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/1061186X.2012.761225

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23336209

http://www.w3.org/2001/XMLSchema#string